We demonstrate a significant increase in anti-tumor activity and overall survival compared to monotherapy alone in CCNE1 amplified OVCA and EMCA PDX models using a low dosing strategy justifying further evaluation in the clinic (Figure 3). The gene discussed is CCNE1; the disease is neoplasm.